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Abstract
Background Low-cost generic drug programs (LCGPs)
increase the accessibility and affordability in the USA of
prescription medication that can treat many common
pediatric conditions. No studies have assessed the preva-
lence and predictors of LCGP use in the pediatric popu-
lation, analyzed trends in LCGP use since their
implementation, or analyzed which medications are most
commonly purchased for children through LCGPs.
Objectives Our objective was to determine the prevalence
of LCGP use in the USA during the period 2007–2012 and
to assess predictors of LCGP use in a nationally repre-
sentative sample of children and adolescents.
Methods We used cross-sectional data from the
2007–2012 Medical Expenditure Panel Survey (MEPS)
and classified each prescription fill as an LCGP or non-
LCGP fill. We assessed the proportions of LCGP fills and
LCGP users each year from 2007 to 2012 and compared
users and non-users during the latest available study cohort
(2011–2012) using chi-squared and t-tests for users. We
used multivariable logistic regression to identify factors
associated with LCGP use in the most recent MEPS panel.
Results Of 2754 children meeting all inclusion criteria,
23.7 % were classified as LCGP users, representing over 10
million adolescent LCGP users over the 2011–2012 period.
LCGP users were significantly more likely to be female,
privately insured, White, residing in urban areas, lacking
prescription drug coverage, and in a higher income bracket
than non-users. Significant predictors of LCGP use included
age, prescription drug coverage, insurance type, race, region
of residence, and number of unique medications used.
Conclusions \While one in four children use LCGPs,
certain subgroups that may benefit the most from the pro-
grams are using them at a lower rate, and use of these
programs has important effects on medication utilization
quality assurance and research.
Key Points
Low-cost generic programs (LCGPs) increase access
to medications, especially for those with lower
income and no insurance, but they introduce the
chance of exposure misclassification if medication
use is unobserved, with implications for patients and
health systems for quality assurance and research.
In the US pediatric population, 23.7 % used at least
one medication filled via an LCGP. However,
uninsured children were half as likely to use LCGPs
as children with private insurance.
Roughly 6 % of all medication fills for children were
obtained through LCGPs, including[10 % of fills for
antidepressants, antibiotics, and cardiovascular
medications with potentially serious adverse drug
effects.
1 Introduction
Low-cost generic drug programs (LCGPs) first appeared in
the USA in mid-2006, with Kmart providing 90 days of
certain generics for $US15; this was shortly followed by
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Wal-Mart’s $US4 program [1]. Generic discount programs
are now in place at almost all major pharmacy chains,
including eight of the top ten largest chain pharmacies in
the nation, and include one-third of the top 100 generics
used by Americans by volume [1–3]. Medications available
through LCGPs can be used to treat many common medical
conditions experienced by children, including infections,
asthma, allergies, and digestive disorders [4–6].
LCGPs have increased the accessibility and affordability
of medications, especially for Americans living in poverty
or without prescription insurance [2]. Given the low costs
of these medications, it is often cheaper for individuals to
purchase prescription medications out of pocket via LCGPs
than to pay the $US10–20 copay to receive medication
through a prescription benefit [2, 7]. A 2011 study esti-
mated potential savings from individuals purchasing med-
ications through LCGPs instead of their insurance
programs and determined that Americans could have saved
over $US1 billion in 2007 alone [8].
Despite this potential for tremendous cost savings, there
is a relative dearth of literature assessing the prevalence of
LCGP use in a nationally representative population. In
2008, over 70 million Americans were estimated to have
used an LCGP to obtain a prescription medication—a fig-
ure that has likely expanded as the number and popularity
of these programs has increased [1, 6, 9]. In a 2008 self-
reported survey, one-third of adults and one-quarter of
children without insurance coverage reported using these
programs, and parents reported use of these programs for
14–23 % of children with private or public insurance [9].
However, given that self-reported surveys are particularly
prone to recall and selection bias, it is difficult to ascertain
whether these estimates accurately represent LCGP use in
the pediatric and adolescent populations.
Use of LCGPs has important ramifications for health
services research reliant on administrative claims data.
Medication paid for out of pocket is a known source of
medication exposure misclassification in administrative
claims, and LCGPs are a common source of out-of-pocket
payments [2, 7]. When individuals fill a medication
through an LCGP, the dispensing pharmacist has no
incentive to file a claim for the medication with the indi-
vidual’s insurer, meaning the medication use will be
unobserved in the pharmaceutical claims data. If children
with different forms of insurance—e.g., public, private, or
uninsured—use LCGPs at different rates, it may lead to
exposure misclassification in administrative claims sour-
ces. Given the expansion of insurance coverage under the
Affordable Care Act (ACA), it is more important than ever
to estimate how often individuals with different forms of
insurance use LCGPs and how this use may impact the
potential for differential exposure misclassification in
claims data [10].
Few studies have assessed the demographic and clinical
characteristics of LCGP users and non-users, and none to
our knowledge have assessed LCGP use specifically in a
pediatric population. Understanding the factors that influ-
ence which individuals currently utilize these programs is a
crucial first step in increasing use amongst patients that
have the most to gain from LCGPs and quantifying the
potential effects that LCGP use may have on the healthcare
system. This cross-sectional study had four objectives: (1)
estimate the prevalence and predictors of LCGP use in a
nationally representative pediatric population; (2) analyze
trends amongst children in LCGP use since they were
implemented in 2006; (3) determine which medications are
most commonly purchased for children through LCGPs;
and (4) assess the potential for exposure misclassification
due to LCGP use.
2 Methods
2.1 Data Source
This study utilized public use data from the Medical
Expenditure Panel Survey (MEPS) for the years
2007–2012. MEPS is a nationally representative survey of
civilian, non-institutionalized individuals in the USA and
includes information on demographics, healthcare utiliza-
tion, medical conditions, and prescription medication use.
MEPS uses an overlapping panel design with a new cohort
(‘panel’) added each year that participates in the survey for
up to 2 years. Data are collected in five rounds throughout
a panel’s 2 years of participation. Medication use is cap-
tured at the pharmacy level and includes all prescriptions
obtained, irrespective of whether an insurance claim was
submitted. Survey sampling and response weights are
included so that population estimates may be obtained.
2.2 Study Subjects and Design
We used a cross-sectional study design to compare dif-
ferences between LCGP users and non-users in the
2011–2012 MEPS panel. In a separate descriptive analysis,
rates of LCGP use from the 2007–2012 data were quanti-
fied to assess trends in the proportions of LCGP fills and
LCGP users over these years. These years were chosen
because 2007 was the first full year in which LCGPs were
available and 2012 is the most recent year of data available
from MEPS. Both analyses had the same inclusion criteria,
which required that individuals were aged 0–17 years,
participated in all five rounds of data collection, and
reported using at least one prescription medication during
their 2-year panel period. The 2011–2012 data panel was
chosen for the cross-sectional analysis as it was the most
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recent data panel available and provided the most up-to-
date analysis of LCGP use in the pediatric population.
Study methods for inclusion of subjects, classification of
LCGP fills, and classification as users and non-users were
consistent across both the cross-sectional and the trend
analysis.
Pharmaceutical utilization was assessed at the individual
level for each year of the study period. Pharmaceutical data
in MEPS include drug name, National Drug Code (NDC),
MEPS round supplied, strength, quantity dispensed, and
days supplied. Each prescription fill included in the MEPS
dataset also includes information regarding the amount
paid by the individual out of pocket and the amount con-
tributed by other sources.
2.3 Use of Low-Cost Generic Programs (LCGP)
Four stipulations were used to define LCGP use: (1) the
total cost of the drug was paid out of pocket (i.e., paid
completely in cash by the customer); (2) the cost of the
drug exactly matched the cost of an LCGP drug as reported
by pharmacies (e.g., $US4 cash payment); (3) the medi-
cation was available through an LCGP from a major chain
pharmacy from 2007 to 2012; and (4) oral medication fills
were dispensed for 30- or 90-day supplies of medications,
with the exception of anti-infectives, contraceptives, and
steroids, which were allowed to vary given the different
days of supply typically dispensed for these classes. LCGP
use was coded at the person level as a binary dependent
variable for any use during the study period and at the
medication level for each medication fill. Pharmaceutical
utilization was determined for medications available from
LCGPs based on Multum Lexicon classification systems
(Cerner MultumTM, Denver, CO, USA). We calculated the
proportion of fills of each medication or medication class
obtained through an LCGP.
2.4 Subject Characteristics
Cohort demographics and characteristics of interest inclu-
ded age, race, sex, family income level, insurance type,
prescription drug coverage, medical conditions, and num-
ber of prescriptions filled. For comparison, the cohort was
stratified by age categories: 0–4, 5–8, 9–12, and
13–17 years. To ensure that individuals were aged
\18 years during the entire period, age was assessed at the
end of the panel for each subject. Insurance was catego-
rized as private, public, or uninsured. Prescription drug
coverage was coded as a binary variable if individuals were
observed to have third-party payers in the MEPS ‘‘Pre-
scribed Medicines’’ file. Family income level was stratified
by the data source as a percentage of the federal poverty
level (FPL): \100, 100–125, 126–200, 201–400, and
[400 % of the FPL. Residence within a metropolitan
statistical area (MSA) was recorded as a binary variable,
and region was categorized by US census regions. Race
was divided between non-Hispanic Whites, Hispanics
(White or Black), African Americans (non-Hispanic),
Asians, and others. Age, family income, region, MSA, and
insurance type were all assessed at the last round of data
collection.
Medical conditions were classified using single-level
Clinical Classification System codes, which are based on
valid International Classification of Disease, 9th Revision,
Clinical Modification (ICD-9-CM) codes [11]. The number
of prescriptions filled and number of unique medications
filled over the 2-year panel were recorded as continuous
measures.
2.5 Data Analysis
The proportion of LCGP uses was calculated as the
proportion of all prescriptions filled via an LCGP in each
year. The proportion of LCGP users was the percent of
the population that filled at least one prescription via an
LCGP. Comparisons were made between LCGP users
and non-users in the 2011–2012 MEPS panel using chi-
squared or t tests. Multivariable logistic regression was
used to identify factors associated with LCGP use in the
2011–2012 panel. Adjusted odds ratios (AORs) and
95 % confidence intervals (CIs) were reported. All data
analyses were conducted using SAS 9.4 (SAS Institute,
Cary, NC, USA) implementing SAS procedures (SUR-
VEYMEANS, SURVEYFREQ, and SURVEYLOGIS-
TIC) that take into account the complex survey design of
MEPS and use the longitudinal survey weights supplied
by MEPS to calculate population estimates over the
2-year period. This manuscript was drafted according to
the STROBE (Strengthening the Reporting of Observa-




In the 2011–2012 MEPS panel, 2754 individuals were aged
0–17 years, participated in all rounds of data collection,
and used at least one prescription medication during the
study period. Applying MEPS person weights, this cohort
represented a weighted population size of 43,020,913
individuals who filled a prescription medication—over half
of the US population aged\18 years (74.2 million) [12].
Of this population, 23.7 % [95 % CI 21.1–26.34 %
(n = 10,196,181)] were classified as LCGP users having
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filled at least one prescription meeting the aforementioned
criteria for an LCGP fill.
User and non-user demographic characteristics are
compared in Table 1. The LCGP user group included a
significantly greater proportion of individuals who were
White (71.3 vs. 57.4 %), were in the highest family income
level (34.0 vs. 21.7 %), had private insurance (83.1 vs.
54.8 %), were female (53.0 vs. 48.5 %), and lived in urban
areas (87.2 vs. 84.3 %). The LCGP non-user group had
significantly more individuals with prescription drug cov-
erage (83.8 vs. 68.7 %) than the user group. LCGP users
tended to fill significantly more medications and used more
unique medications than non-users. A significantly greater
proportion of LCGP users experienced ear infections (33.6
vs. 23.2 %), respiratory infections (73.3 vs. 58.2 %), other
general infections (24.5 vs. 15.9 %), and mood disorders
(7.1 vs. 2.1 %).
3.2 Medication Use
The study cohort (n = 2754) filled 20,739 prescriptions
during the 2011–2012 panel period. Of the 20,739 medi-
cation fills, 66.1 % (n = 13,706) were for medications
available through LCGPs. Of all fills for medications
available through LCGPs, 8.6 % were actually purchased
through LCGPs. Figure 1 displays the proportions of
LCGP fills and LCGP users graphed against the average
total prescription fills per person per year in each year from
2007 to 2012. The proportion of LCGP fills out of all
medications available through LCGPs decreased slightly
from 8.2 % of fills in 2007 to 8.1 % of fills in 2012. Over
2007–2012, the proportion of LCGP users also decreased
from 16 % in 2007 to 14 % in 2012. While the proportions
of LCGP fills and LCGP users both decreased slightly from
2007 to 2012, the number of prescription fills per person
per year remained relatively stable at an approximate
average of 3.4 fills per person per year.
Figure 2 shows the proportion of fills of each medica-
tion class that were purchased through LCGPs. The
majority of metformin fills were obtained through LCGPs
(65.7 %). Over 25 % of fills for beta-blockers (44.4 %),
ipratropium (33.3 %), diuretics (31.8 %), and analgesic
combinations (27.3 %) were purchased through LCGPs.
More than 15 % of fills for levothyroxine (18.2 %),
selective serotonin reuptake inhibitors (SSRIs) (18.0 %),
tetracyclines (17.9 %), penicillins (17.7 %), topical anes-
thetics (17.0 %), contraceptives (16.0 %), and oral anti-
infectives (15.3 %) were obtained through LCGPs. More
than 10 % of fills for topical anti-infectives (14.2 %),
steroids (13.4 %), antifungals (11.9 %), topical acne
medications (11.4 %), and tricyclic antidepressants (TCAs)
(10.8 %) were filled through LCGPs. Other medication
classes with fewer than 10 % of fills through LCGPs
included sulfamethoxazole/trimethoprim, topical steroids,
fluoroquinolones, anti-emetics, urinary antispasmodics,
topical antifungals, cephalosporins, angiotensin-converting
enzyme inhibitors, anticonvulsants, and albuterol, among
others.
3.3 Determinants of LCGP Use
After adjusting for all covariates, age, prescription drug
coverage, insurance type, race, region, and the number of
unique medications filled all significantly predicted LCGP
use. The overall model c-statistic is 0.79, reflecting strong
discrimination between users and non-users. Results of the
full regression model are presented in Table 2.
Children aged 9–12 years were significantly less likely
to use LCGPs than the reference category of children aged
0–4 years (AOR 0.59 [95 % CI 0.38–0.91]) and had lower
odds than the groups aged 5–8 and 13–17 years. Individ-
uals without prescription drug coverage were over 200 %
more likely than those with coverage to use LCGPs [95 %
CI 2.35–4.52]. Publicly insured children (AOR 0.27 [95 %
CI 0.18–0.39]) and those without any form of insurance
(AOR 0.46 [95 % CI 0.23–0.93]) were both significantly
less likely to fill prescriptions through LCGPs. Asian
children (AOR 0.44 [95 % CI 0.20–0.99]) were also sig-
nificantly less likely to fill medications through LCGPs
than the White reference category. Individuals residing in
the Midwest were less likely to use LCGPs than those
living in the Northeast reference category (AOR 0.69
[95 % CI 0.48–0.99]). Each additional unique medication
filled increased the odds of LCGP use by 33 % (AOR 1.33
[95 % CI 1.25–1.41]).
4 Discussion
Our study found that nearly one in four people aged\18
years who used prescription drugs filled at least one med-
ication through an LCGP during a 2-year period. Of all fills
for medications available through LCGPs, 8.6 % were
purchased through LCGPs, or 5.7 % of all medications
were filled through LCGPs.
No known studies have assessed LCGP medication use
in the pediatric and adolescent populations. One survey
found that parents reported that their children with no
insurance (24 %), public insurance (23 %), and private
insurance (14 %) were using low-cost generics [9]. How-
ever, this survey did not investigate specific medication use
in this population or consider other subject characteristics.
Our study used data collected at the pharmacy level, which
included specific payment sources, to determine program
use. Applying MEPS person weights, we found that 32.0 %
of those with private insurance, 19.2 % of those without
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Table 1 Characteristics of users and non-users of low-cost generic programs in the US pediatric population (age\18 years) during 2011–2012
Characteristic LCGP users Non-users
N % N (weighted)a % (weighted)a N % N (weighted)a % (weighted)a
Overall sample (n = 2754) 525 19.1 10,196,181 23.7 2229 80.9 32,824,732 76.3
Age
0–4 147 28.0 2,924,435.00 28.7 645 28.9 8,761,071 26.7
5–8 131 25.0 2,320,994.00 22.8 555 25.1 7,822,871 23.8
9–12 102 19.4 1,858,311.00 18.2 496 22.4 7,464,306 22.7
13–17 145 27.6 3,092,442.00 30.3 533 23.7 8,776,484 26.7
Sex*
Male 252 48.0 4,787,395 47.0 1185 53.2 16,897,491 51.5
Female 273 52.0 5,408,786 53.0 1044 46.8 15,927,241 48.5
Insurance*
Private 376 71.6 8,469,703 83.1 846 38.0 17,976,449 54.8
Public 132 25.1 1,474,663 14.5 1324 59.4 13,791,663 42.0
Uninsured 17 3.2 251,814 2.5 59 2.6 1,056,620 3.2
Prescription coverage*
No coverage 175 33.3 3,194,053 31.3 280 12.6 5,313,686 16.2
Coverage 350 66.7 7,002,128 68.7 1949 87.4 27,511,046 83.8
Race*
Non-Hispanic White 266 50.7 7,269,050 71.3 775 34.8 18,829,880 57.4
Hispanic (White or Black) 148 28.2 1,615,182 15.8 800 35.9 6,888,112 21.0
African American 68 13.0 793,037 7.8 474 21.3 4,641,232 14.1
Asian 22 4.2 240,551 2.4 81 3.6 1,196,827 3.6
Other 21 4.0 278,360 2.7 99 4.4 1,268,681 3.9
Region*
Northeast 73 13.9 1,561,263 15.3 309 13.9 4,687,402 14.3
Midwest 107 20.4 2,226,796 21.8 481 21.6 7,797,175 23.8
South 179 34.1 3,768,451 37.0 873 39.2 13,388,854 40.8
West 166 31.6 2,639,671 25.9 566 25.4 6,951,300 21.2
Income category*
\100 % of FPL 96 18.3 1,166,649 11.4 875 39.3 8,581,904 26.1
100–125 % of FPL 20 3.8 308,487 3.0 173 7.8 1,937,629 5.9
125–200 % of FPL 88 16.8 1,507,038 14.8 384 17.2 5,026,781 15.3
200–400 % of FPL 186 35.4 3,744,382 36.7 503 22.6 10,164,330 31.0
[400 % of FPL 135 25.7 3,469,626 34.0 294 13.2 7,114,087 21.7
MSA*
Rural 55 10.5 1,300,186 12.8 321 14.4 5,161,161 15.7
Urban 470 89.5 8,895,995 87.2 1908 85.6 27,663,570 84.3
Conditions
Infections* 121 23.0 2,501,823 24.5 335 15.0 5,233,414 15.9
Mental disorder 74 14.1 1,597,277 15.7 360 16.2 5,870,899 17.9
ADHD 46 8.8 832,986 8.2 248 11.1 3,933,646 12.0
Mood disorder* 32 6.1 728,963 7.1 52 2.3 692,575 2.1
Headache 24 4.6 564,701 5.5 82 3.7 1,371,709 4.2
Ear infection* 166 31.6 3,422,828 33.6 476 21.4 7,601,497 23.2
Pneumonia 28 5.3 667,777 6.5 77 3.5 1,255,095 3.8
Respiratory infection* 365 69.5 7,475,498 73.3 1229 55.1 19,117,431 58.2
Asthma 95 18.1 1,518,811 14.9 387 17.4 5,257,033 16.0
Arthritis 43 8.2 971,159 9.5 148 6.6 2,353,757 7.2
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insurance, and only 9.7 % of those with public insurance
used LCGPs (Table 1). In addition to these differences, the
overall proportion of users in our study (23.7 %) was
slightly higher than the prevalence of use determined in the
prior study (18 %) [9].
Children who lack any form of insurance or prescription
drug coverage may stand to benefit the most from the
inexpensive medications offered through LCGPs. Given
the findings that lack of prescription drug coverage is a
significant predictor of LCGP use (AOR 3.26 [95 % CI
2.35–4.52]; Table 2), and that nearly one in five uninsured
children used an LCGP from 2011 to 2012 (Table 1), it can
be seen that this population is indeed using these programs.
However, in adjusted analysis, the uninsured pediatric
population had roughly 50 % lower odds of using LCGP
medications than privately insured children (Table 2).
Furthermore, the finding that most LCGP users fall into the
two highest income levels suggests that individuals who
could benefit most from these programs are not in fact
using them as often as they could, suggesting differential
access to care among insurance and family income groups
[13, 14].
Previous studies have reported cost and access to med-
ications as significant barriers to proper management of
Table 1 continued
Characteristic LCGP users Non-users
N % N (weighted)a % (weighted)a N % N (weighted)a % (weighted)a
Diabetes 8 1.5 135,413 0.5 9 0.4 151,559 0.5
Nutritional deficiencies* 12 1.7 242,186 2.4 41 1.8 198,243 0.6
*Epilepsy 9 2.3 229,048 2.2 13 0.6 472,714 1.4
Total number of medication fills* (median [IQR]) 4 (2–10) 4 (2–10) 3 (1–7) 2 (1–7)
Unique medications used* (median [IQR]) 3 (2–5) 2 (1–4) 2 (1–3) 1 (1–3)
Percentages not adding to 100 % are due to rounding
ADHD attention-deficit hyperactivity disorder, FPL federal poverty limit, IQR interquartile range, LCGP low-cost generic program, MSA
metropolitan statistical area
a MEPS data are weighted based on demographics (e.g., race, sex, age, etc.) to be nationally representative. The total raw sample included 2754
subjects who, when weighted, represent 43,020,913 subjects in the USA
* p\ 0.05 for weighted group comparison of LCGP users vs. non-users on all characteristics
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Average Prescription Fills per Person
Proportion of Users
Proportion of Fills
Fig. 1 Trend of the proportion
of low-cost generic program
(LCGP) users and fills and
overall medication utilization in
each year 2007–2012.
Proportion of users is the
proportion of the pediatric
population that filled at least one
prescription through an LCGP
in that year. Proportion of fills is
the proportion of prescription
fills obtained via an LCGP out
of all prescription fills that are
available through LCGPs in the
pediatric population for that
year
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pediatric conditions [15–17]. Inexpensive medications
offered through LCGPs improve access to and ameliorate
the cost burden of prescription medications for children
across the USA. Several findings of this study indicate that
LCGPs are commonly being used to assist with the man-
agement of both chronic and acute illnesses. Results of this
study indicate that rates of LCGP use in the 2011–2012
MEPS panel are markedly higher in children with diseases
that can be treated with medications available through
LCGPs than the rate in the overall pediatric population
(23.7 %). For example, 55.0 % of children with nutritional
deficiencies were LCGP users, as well as 47.2 % of those
with diabetes, 34.7 % of those with pneumonia, 32.6 % of
those with epilepsy, 32.3 % of those with general infec-
tions, 31.0 % of those with ear infections, 29.2 % of
children with arthritis, and 28.1 % of those with respiratory
infections (Table 1).
Despite the benefits of greater LCGP use in the pediatric
population, astute researchers must be wary of the potential
for exposure misclassification that these programs present
when using certain data sources. True medication utiliza-
tion may not be captured in the administrative claims for
individuals who use LCGPs, which may impact the find-
ings of health services research relying on these data
sources [18, 19]. Medication use in this age group includes
medication classes with significant risk profiles and medi-
cations used to treat serious medical conditions. Especially
for privately insured children, who according to our find-
ings use LCGPs at a greater rate than publicly insured or
uninsured children, exposure misclassification due to
LCGP use may circumvent the added protections (i.e.,
surveillance for drug interactions, etc.) provided by the
claims adjudication process. For children with public forms
of insurance, exposure misclassification due to LCGP use
may have important ramifications on the calculation of
quality metrics that Medicaid plans are required to report
under the ACA [20, 21]. Using Fig. 2, the potential impact
of misclassification can be estimated given that the
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proportion of fills of each medication class filled through
an LCGP provides an estimate of the number of exposures
that may go unclassified.
Our study is subject to some limitations. It may remain
possible that not all medication use is recorded if all
pharmacies used were not surveyed. Our study definition of
LCGP use may allow for overestimation of use if only
pricing is considered. However, this effect is mitigated by
requiring specific quantities supplied for oral medications.
Finally, it is possible that some individuals exclusively use
pharmacies in which LCGPs are not available and thus this
population was never eligible for inclusion in the LCGP
user cohort.
5 Conclusions
This study found a high rate of LCGP users among a
nationally representative sample of children and adoles-
cents. Low-cost generics increase the affordability and
Table 2 Multivariable logistic
regression results of predictive
characteristics for LCGP use in
the United States pediatric
population in 2011–2012
Characteristic Adjusted OR 95 % wald confidence limits
Lower Upper
Age
0–4 Ref. Ref. Ref.
5–8 0.86 0.58 1.28
9–12 0.59 0.38 0.91
13–17 0.78 0.55 1.10
Sex
Male Ref. Ref. Ref.
Female 1.13 0.88 1.45
Prescription drug coverage
Prescription coverage Ref. Ref. Ref.
No prescription coverage 3.26 2.35 4.52
Insurance type
Private Ref. Ref. Ref.
Public 0.27 0.18 0.39
Uninsured 0.46 0.23 0.93
Income category
\100 % of FPL Ref. Ref. Ref.
100–125 % of FPL 1.02 0.50 2.10
125–200 % of FPL 1.41 0.90 2.19
200–400 % of FPL 1.29 0.83 2.02
[400 % of FPL 1.46 0.89 2.39
Race
Non-Hispanic White Ref. Ref. Ref.
Hispanic (White or Black) 1.02 0.71 1.46
African American (non-Hispanic) 0.70 0.45 1.10
Asian 0.44 0.20 0.99
Other 0.67 0.37 1.21
MSA
Rural Ref. Ref. Ref.
Urban 1.17 0.76 1.82
Region
Northeast Ref. Ref. Ref.
Midwest 0.69 0.48 0.99
South 0.82 0.55 1.21
West 1.17 0.79 1.72
Number of unique meds 1.33 1.25 1.41
FPL federal poverty level, LCGP low-cost generic program, MSA metropolitan statistical area
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access to medications where high costs may prohibit
treatment. However, considering the implications for
patients and the healthcare system as a whole, programs
should be implemented so that medication use data are
captured and are accounted for in drug policy and phar-
macoepidemiological research. Future studies should
empirically demonstrate the effects of differential exposure
misclassification on the results of claims-based research.
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